UNICYCIVE THERAPEUTICS, INC. (UNCY) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$10.14M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$8.44M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$7.34M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$6.96M; Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2021-12-31 to 2022-12-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$10.14M | (m) | (m) | (m) | -$1.00K* | -$7.60M* | (m) | $2.79M | (m) | (m) |
|---|
| 2026-03-31 | Reported | (m) | -$8.44M | (m) | (m) | (m) | $8.00K | -$6.24M | (m) | $1.61M | (m) | (m) |
|---|
| 2025-09-30 | Reported | (m) | -$7.34M | (m) | (m) | (m) | $2.00K* | -$5.96M* | (m) | $2.96M | (m) | (m) |
|---|
| 2025-06-30 | Reported | (m) | -$6.96M | (m) | (m) | (m) | $6.00K* | -$8.42M* | (m) | $1.75M | (m) | (m) |
|---|
| 2025-03-31 | Reported | (m) | -$7.99M | (m) | (m) | (m) | $16.00K | -$8.90M | (m) | $2.17M | (m) | (m) |
|---|
| 2024-09-30 | Reported | (m) | -$6.25M | (m) | (m) | (m) | $24.00K* | -$9.25M* | (m) | $3.04M | (m) | (m) |
|---|
| 2024-06-30 | Reported | (m) | -$7.40M | (m) | (m) | (m) | $20.00K* | -$6.32M* | (m) | $4.87M | (m) | (m) |
|---|
| 2024-03-31 | Reported | (m) | -$9.20M | (m) | (m) | (m) | $6.00K | -$6.46M | (m) | $6.81M | (m) | (m) |
|---|
| 2023-09-30 | Reported | (m) | -$5.94M | (m) | (m) | (m) | $0.00* | -$4.42M* | (m) | $3.37M | $479.00K | (m) |
|---|
| 2023-06-30 | Reported | (m) | -$4.32M | (m) | (m) | (m) | (m) | -$5.50M* | (m) | $2.27M | $193.00K | (m) |
|---|
| 2023-03-31 | Reported | (m) | -$4.20M | (m) | (m) | (m) | (m) | -$3.92M | (m) | $3.03M | $62.00K | (m) |
|---|
| 2022-09-30 | Reported | (m) | -$5.55M | (m) | (m) | (m) | $0.00* | -$3.56M* | (m) | $4.80M | $163.00K | (m) |
|---|
| 2022-06-30 | Reported | (m) | -$3.64M | (m) | (m) | (m) | $0.00* | -$3.05M* | (m) | $1.86M | $62.00K | (m) |
|---|
| 2022-03-31 | Reported | (m) | -$3.54M | (m) | (m) | (m) | $2.00K | -$2.96M | (m) | $1.93M | $191.00K | (m) |
|---|
| 2021-09-30 | Reported | (m) | -$4.71M | (m) | (m) | (m) | (m) | -$3.47M* | (m) | $3.78M | $72.00K | (m) |
|---|
| 2021-06-30 | Reported | (m) | -$779.00K | (m) | (m) | (m) | (m) | -$217.00K* | (m) | $493.00K | $23.00K | (m) |
|---|
| 2021-03-31 | Reported | (m) | -$731.00K | (m) | (m) | (m) | (m) | -$673.00K | (m) | $450.00K | $18.00K | (m) |
|---|
| 2020-09-30 | Reported | (m) | -$626.00K | (m) | (m) | (m) | (m) | -$706.00K* | (m) | $304.00K | $15.00K | (m) |
|---|
| 2020-06-30 | Reported | (m) | -$336.00K | (m) | (m) | (m) | (m) | (m) | (m) | $182.00K | $17.00K | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$29.52M | (m) | (m) | (m) | $24.00K | -$31.32M | (m) | $9.12M | (m) | (m) |
|---|
| 2024-12-31 | Reported | (m) | -$32.12M | (m) | (m) | (m) | $72.00K | -$28.57M | (m) | $20.01M | (m) | (m) |
|---|
| 2023-12-31 | Reported | (m) | -$20.77M | (m) | (m) | (m) | $12.00K | -$18.28M | (m) | $12.90M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$17.62M | (m) | (m) | (m) | -1853.21% | $2.00K | -$15.65M | (m) | $12.44M | $383.00K | (m) |
|---|
| 2021-12-31 | Reported | -$8.51M | (m) | (m) | (m) | (m) | $29.00K | -$5.77M | (m) | $6.08M | $245.00K | (m) |
|---|
| 2020-12-31 | Reported | (m) | -$2.02M | (m) | (m) | (m) | (m) | -$1.46M | (m) | $1.01M | $58.00K | (m) |
|---|